<iati-activities version="2.03">
 <iati-activity default-currency="CAD" dstore:dataset="idrccrdi-act-2016-6" dstore:index="265" hierarchy="1" iati-activities:generated-datetime="2020-03-10T18:57:24Z" iati-activities:version="2.02" last-updated-datetime="2019-10-07T00:00:00Z" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <activity-date iso-date="2019-10-04" type="2"></activity-date>
  <activity-date iso-date="2019-11-01" type="4"></activity-date>
  <activity-scope code="4"></activity-scope>
  <activity-status code="3"></activity-status>
  <collaboration-type code="1"></collaboration-type>
  <conditions attached="0"></conditions>
  <contact-info type="1">
   <email>info@idrc.ca</email>
   <mailing-address>
    <narrative xml:lang="EN">PO Box 8500, Ottawa ON Canada, K1G 3H9</narrative>
    <narrative xml:lang="FR">CP 8500, Ottawa ON Canada, K1G 3H9</narrative>
   </mailing-address>
   <organisation>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   </organisation>
   <telephone>(+1) 613-236-6163</telephone>
   <website>http://www.idrc.ca</website>
  </contact-info>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-finance-type code="110"></default-finance-type>
  <default-flow-type code="10"></default-flow-type>
  <default-tied-status code="5"></default-tied-status>
  <description type="1">
   <narrative xml:lang="EN">This project convened a scientific meeting of international researchers, infectious disease experts, and officials from the Democratic Republic of the Congo (DRC) to discuss the therapeutic potential of quercetin, a compound that is being used experimentally to treat and prevent Ebola. 


The two-day meeting sought to review and discuss the clinical profile of quercetin, its potential as a preventive and therapeutic agent against Ebola, and the scientific, ethical, and logistical considerations of integrating this drug into the current response efforts to the ongoing Ebola outbreak in the DRC. This meeting will help to inform global health stakeholders who are considering adopting and rolling out experimental therapies in public health emergencies, and the risks and opportunities that lie within such actions.</narrative>
   <narrative xml:lang="FR">Dans le cadre de ce projet, des chercheurs internationaux, des sp&#xE9;cialistes des maladies infectieuses et des repr&#xE9;sentants de la R&#xE9;publique d&#xE9;mocratique du Congo (RDC) se sont r&#xE9;unis pour discuter du potentiel th&#xE9;rapeutique de la quercitrine, un compos&#xE9; utilis&#xE9; de fa&#xE7;on exp&#xE9;rimentale pour traiter et pr&#xE9;venir la maladie &#xE0; virus Ebola. 


La r&#xE9;union de deux jours visait &#xE0; examiner le profil clinique de la quercitrine, &#xE0; discuter de son potentiel en tant qu&#x2019;agent pr&#xE9;ventif et th&#xE9;rapeutique contre la maladie &#xE0; virus Ebola, et &#xE0; &#xE9;tudier les consid&#xE9;rations scientifiques, &#xE9;thiques et logistiques de l&#x2019;int&#xE9;gration de ce m&#xE9;dicament dans les efforts actuels de r&#xE9;ponse &#xE0; l&#x2019;&#xE9;pid&#xE9;mie de la maladie &#xE0; virus Ebola en cours en RDC. Cette r&#xE9;union permettra d&#x2019;informer les intervenants de la sant&#xE9; mondiale qui envisagent d&#x2019;adopter et de d&#xE9;ployer des th&#xE9;rapies exp&#xE9;rimentales dans les situations d&#x2019;urgence en sant&#xE9; publique, et de faire conna&#xEE;tre les risques et les possibilit&#xE9;s qui d&#xE9;coulent de telles actions.</narrative>
  </description>
  <iati-identifier>XM-DAC-301-2-109278-001</iati-identifier>
  <participating-org role="4" type="24">
   <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
  </participating-org>
  <participating-org role="2" type="24">
   <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Canada. Parliament</narrative>
   <narrative xml:lang="FR">Canada. Parlement</narrative>
  </participating-org>
  <participating-org role="3" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </participating-org>
  <policy-marker code="1" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="5" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1"></policy-marker>
  <recipient-country code="CD" percentage="100"></recipient-country>
  <reporting-org ref="XM-DAC-301-2" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </reporting-org>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <sector code="1" percentage="100" vocabulary="99">
   <narrative xml:lang="EN">Other</narrative>
   <narrative xml:lang="FR">Autre</narrative>
  </sector>
  <title>
   <narrative xml:lang="EN">International workshop on the use of quercetin as an experimental therapy to treat Ebola</narrative>
   <narrative xml:lang="FR">Atelier international sur l&#x2019;utilisation de la quercitrine comme th&#xE9;rapie exp&#xE9;rimentale pour traiter la maladie &#xE0; virus Ebola</narrative>
  </title>
  <transaction>
   <disbursement-channel code="2"></disbursement-channel>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <transaction-date iso-date="2019-10-07"></transaction-date>
   <transaction-type code="2"></transaction-type>
   <value currency="CAD" value-date="2019-10-07">20000</value>
  </transaction>
  <transaction>
   <disbursement-channel code="2"></disbursement-channel>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="FR">Institut de recherches cliniques de Montr&#xE9;al</narrative>
   </receiver-org>
   <transaction-date iso-date="2019-10-07"></transaction-date>
   <transaction-type code="4"></transaction-type>
   <value currency="CAD" value-date="2019-10-07">20000</value>
  </transaction>
 </iati-activity>
</iati-activities>
